Indeed, therapies targeting immune-checkpoint molecules (e.g., programmed cell death 1 (PD-1), programmed cell death ligand 1 (PD-L1), and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4)) are currently used in clinical practice for the treatment of several cancers [37]. Here, CD274 is linked to cancer.